Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

NCT00765947 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

256

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension ( Mild to Moderate)

Interventions

DRUG: Aliskiren
DRUG: Hydrochlorothiazide
DRUG: Amlodipine

Sponsor

Novartis